 | Up a level |
2014
Robak, Tadeusz, Hellman, Andrzej, Loscertales, Javier, Lech-Maranda, Ewa 
ORCID: 0000-0001-9592-0851, Pagel, John M., Mato, Anthony R., Byrd, John C., Awan, Farrukh ORCID: 0000-0003-1813-9812, Hebart, Holger, Garcia-Marco, Jose A., Hill, Brian T., Hallek, Michael, Stromatt, Scott and Kloczko, Janusz
(2014).
Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR (TM) Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results.
Blood, 124 (21).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
2012
Awan, Farrukh ORCID: 0000-0003-1813-9812, Jaeger, Ulrich, Rifkin, Robert, Thirman, Michael J., Byrd, John C., Hallek, Michael, Stromatt, Scott and Pagel, John M.
(2012).
Phase 1b Study of TRU-016, an Anti-CD37 SMIP (TM) Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia.
Blood, 120 (21).
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 0006-4971